These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 37561950)

  • 21. Value of Knowing: Health-Related Behavior Changes following Amyloid PET Results Disclosure in Mild Cognitive Impairment.
    Wang Y; Ren D; Roberts JS; Tamres LK; Lingler JH
    J Prev Alzheimers Dis; 2024; 11(4):958-965. PubMed ID: 39044506
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 18F PET with florbetapir for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).
    Martínez G; Vernooij RW; Fuentes Padilla P; Zamora J; Bonfill Cosp X; Flicker L
    Cochrane Database Syst Rev; 2017 Nov; 11(11):CD012216. PubMed ID: 29164603
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of amyloid on memory and non-memory decline from preclinical to clinical Alzheimer's disease.
    Lim YY; Maruff P; Pietrzak RH; Ames D; Ellis KA; Harrington K; Lautenschlager NT; Szoeke C; Martins RN; Masters CL; Villemagne VL; Rowe CC;
    Brain; 2014 Jan; 137(Pt 1):221-31. PubMed ID: 24176981
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chinese Preclinical Alzheimer's Disease Study (C-PAS): Design and Challenge from PET Acceptance.
    Cui L; Huang L; Pan FF; Wang Y; Huang Q; Guan YH; Lo CZ; Guo YH; Chan AS; Xie F; Guo QH
    J Prev Alzheimers Dis; 2023; 10(3):571-580. PubMed ID: 37357299
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Assessment of the Incremental Diagnostic Value of Florbetapir F 18 Imaging in Patients With Cognitive Impairment: The Incremental Diagnostic Value of Amyloid PET With [18F]-Florbetapir (INDIA-FBP) Study.
    Boccardi M; Altomare D; Ferrari C; Festari C; Guerra UP; Paghera B; Pizzocaro C; Lussignoli G; Geroldi C; Zanetti O; Cotelli MS; Turla M; Borroni B; Rozzini L; Mirabile D; Defanti C; Gennuso M; Prelle A; Gentile S; Morandi A; Vollaro S; Volta GD; Bianchetti A; Conti MZ; Cappuccio M; Carbone P; Bellandi D; Abruzzi L; Bettoni L; Villani D; Raimondi MC; Lanari A; Ciccone A; Facchi E; Di Fazio I; Rozzini R; Boffelli S; Manzoni L; Salvi GP; Cavaliere S; Belotti G; Avanzi S; Pasqualetti P; Muscio C; Padovani A; Frisoni GB;
    JAMA Neurol; 2016 Dec; 73(12):1417-1424. PubMed ID: 27802513
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of imaging biomarkers for Alzheimer's disease: amyloid imaging with [18F]florbetapir positron emission tomography and magnetic resonance imaging voxel-based analysis for entorhinal cortex atrophy.
    Tateno A; Sakayori T; Kawashima Y; Higuchi M; Suhara T; Mizumura S; Mintun MA; Skovronsky DM; Honjo K; Ishihara K; Kumita S; Suzuki H; Okubo Y
    Int J Geriatr Psychiatry; 2015 May; 30(5):505-13. PubMed ID: 25043833
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association Between Ambient Air Pollution and Amyloid Positron Emission Tomography Positivity in Older Adults With Cognitive Impairment.
    Iaccarino L; La Joie R; Lesman-Segev OH; Lee E; Hanna L; Allen IE; Hillner BE; Siegel BA; Whitmer RA; Carrillo MC; Gatsonis C; Rabinovici GD
    JAMA Neurol; 2021 Feb; 78(2):197-207. PubMed ID: 33252608
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Imaging characteristic of dual-phase (18)F-florbetapir (AV-45/Amyvid) PET for the concomitant detection of perfusion deficits and beta-amyloid deposition in Alzheimer's disease and mild cognitive impairment.
    Lin KJ; Hsiao IT; Hsu JL; Huang CC; Huang KL; Hsieh CJ; Wey SP; Yen TC
    Eur J Nucl Med Mol Imaging; 2016 Jul; 43(7):1304-14. PubMed ID: 27003417
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Amnestic MCI patients' experiences after disclosure of their amyloid PET result in a research context.
    Vanderschaeghe G; Schaeverbeke J; Bruffaerts R; Vandenberghe R; Dierickx K
    Alzheimers Res Ther; 2017 Dec; 9(1):92. PubMed ID: 29197423
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Perspectives From Black and White Participants and Care Partners on Return of Amyloid and Tau PET Imaging and Other Research Results.
    Rahman-Filipiak A; Lesniak M; Sadaghiyani S; Roberts S; Lichtenberg P; Hampstead BM
    Alzheimer Dis Assoc Disord; 2023 Oct-Dec 01; 37(4):274-281. PubMed ID: 37890053
    [TBL] [Abstract][Full Text] [Related]  

  • 31. FDG-PET and CSF biomarker accuracy in prediction of conversion to different dementias in a large multicentre MCI cohort.
    Caminiti SP; Ballarini T; Sala A; Cerami C; Presotto L; Santangelo R; Fallanca F; Vanoli EG; Gianolli L; Iannaccone S; Magnani G; Perani D;
    Neuroimage Clin; 2018; 18():167-177. PubMed ID: 29387532
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Amyloid-β assessed by florbetapir F 18 PET and 18-month cognitive decline: a multicenter study.
    Doraiswamy PM; Sperling RA; Coleman RE; Johnson KA; Reiman EM; Davis MD; Grundman M; Sabbagh MN; Sadowsky CH; Fleisher AS; Carpenter A; Clark CM; Joshi AD; Mintun MA; Skovronsky DM; Pontecorvo MJ;
    Neurology; 2012 Oct; 79(16):1636-44. PubMed ID: 22786606
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Characterizing brain tau and cognitive decline along the amyloid timeline in Alzheimer's disease.
    Cody KA; Langhough RE; Zammit MD; Clark L; Chin N; Christian BT; Betthauser TJ; Johnson SC
    Brain; 2024 Jun; 147(6):2144-2157. PubMed ID: 38667631
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Predicting cognitive decline: Which is more useful, baseline amyloid levels or longitudinal change?
    Chen G; McKay NS; Gordon BA; Liu J; Joseph-Mathurin N; Schindler SE; Hassenstab J; Aschenbrenner AJ; Wang Q; Schultz SA; Su Y; LaMontagne PJ; Keefe SJ; Massoumzadeh P; Cruchaga C; Xiong C; Morris JC; Benzinger TLS
    Neuroimage Clin; 2024; 41():103551. PubMed ID: 38150745
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Continuity of care (COC) and amyloid-β PET scan: the CARE-IDEAS study.
    O'Brien EC; Ford CB; Sorenson C; Jutkowitz E; Shepherd-Banigan M; Van Houtven C
    Alzheimers Res Ther; 2023 Jan; 15(1):6. PubMed ID: 36611213
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Quantitative Brain Amyloid Measures Predict Time-to-Progression from Amnestic Mild Cognitive Impairment to Alzheimer's Disease.
    Jun S; Kim H; Kim BS; Yoo BG; Lee WG;
    J Alzheimers Dis; 2019; 70(2):477-486. PubMed ID: 31256127
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of Visual and Quantitative Florbetapir F 18 Positron Emission Tomography Analysis in Predicting Mild Cognitive Impairment Outcomes.
    Schreiber S; Landau SM; Fero A; Schreiber F; Jagust WJ;
    JAMA Neurol; 2015 Oct; 72(10):1183-90. PubMed ID: 26280102
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Utility of Amyloid Positron Emission Tomography Imaging in Older Adults With Epilepsy and Cognitive Decline.
    Sarkis RA; Gale SA; Yang HS; Lam AD; Singhal T; Cicero S; Willment K; McGinnis SM
    Am J Alzheimers Dis Other Demen; 2023; 38():15333175231160005. PubMed ID: 36892007
    [TBL] [Abstract][Full Text] [Related]  

  • 39. "And Does That Necessarily Mean Absolutely Alzheimer's?" An Analysis of Questions Raised Following Amyloid PET Results Disclosure.
    Kim JE; Tamres LK; Orbell SL; Cheng RZ; Klunk WE; Aizenstein HJ; Butters MA; McDade E; Lingler JH
    Am J Geriatr Psychiatry; 2024 Jan; 32(1):45-54. PubMed ID: 37634955
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.